The Committee for Medicinal Products for Human Use (CHMP) has issued an opinion opposing Amylyx Pharmaceuticals’ bid for conditional European Union approval of AMX0035, its oral treatment to slow the progression of amyotrophic lateral sclerosis (ALS). The negative recommendation from the advisory committee, an arm of the…
EMA branch opposes conditional approval of AMX0035 in Europe
As I consider the progress we’ve made on ALS, I can’t help wondering if our overall awareness will continue to grow and lead us to even more sensitivity and advocacy. What real action will take place? Will initiatives be developed and sustained? Will we patients be closer to…
The first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating VTX3232, Ventyx Biosciences’ investigational oral therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Top-line data from the trial are expected in the first half of 2024. “VTX3232 is our fourth internally discovered…
Magnetic stimulation restored the health of lab-grown motor neurons — the muscle-controlling nerve cells that die in amyotrophic lateral sclerosis (ALS) — derived from people with familial ALS, according to a proof-of-concept study. The approach improved several biological processes in motor neurons, including the movement of cellular components along…
Ever since my husband Todd’s ALS led to his paralysis, it has been hard for him to get comfortable. This is especially true now that he wears a mask nearly 24/7 for noninvasive ventilation support. For years, I’ve jumped into action when he calls me to swat a…
Albrioza, the approved treatment for amyotrophic lateral sclerosis (ALS) formerly known as AMX0035, is one giant step closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Amylyx Pharmaceuticals. Amylyx has reached an agreement with the pan-Canadian Pharmaceutical Alliance, or pcPA —…
PEG10, an ancient, virus-like protein that supports the development of the placenta, appears to also participate in the nerve cell loss associated with amyotrophic lateral sclerosis (ALS), researchers discovered. ALS-causing mutations in the UBQLN2 gene were found to prevent the proper degradation of PEG10. This led to a…
The other day, right in the middle of doing my daily chair exercises, I had to stop and turn down the volume of my mind’s inner critic. Because I was feeling a little sluggish and off balance, the voice in my head was absolutely convinced that my ALS symptoms…
The first text message my late husband, Jeff, ever sent me was just one word. We’d had our first date the previous evening, and our dinner at a sidewalk restaurant on a mild autumn evening in Alexandria, Virginia, was full of laughter. I was happy to see his text the…
BenevolentAI is advancing BEN-34712, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), to late-stage preclinical studies. The studies are expected to support a future investigational new drug (IND) application, a formal request to the U.S. Food and Drug Administration (FDA) to test a potential new treatment in clinical…
Recent Posts
- Grants support next generation of ALS researchers in Canada
- ALS research wins big bucks with $313M in new US government funding
- Guest Voice: I’m leaving behind a legacy of love through letters
- ALS report cards show how US states fall short on patient support
- Feeding wildlife reminded me what’s important in life after ALS